Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease
that affects more than a quarter of the global population and whose prevalence is increasing …

MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to
today, the most effective treatment is weight loss. Weight loss interventions are moving from …

Weight loss achieved through a combination of healthy eating patterns that encompass the
principles of the Mediterranean diet and regular physical activity is the most evidence-based …

Non-alcoholic fatty liver disease (NAFLD) is a major public health issue worldwide. It is the
most common liver disease in Western countries, andits global prevalence is estimated to be …

Objectives Intermittent fasting (IF) regimens have been hypothesized to influence several
markers of cardiometabolic and liver function. The objective of our meta-analysis was to …

Background The current obesity pandemic has given rise to associated comorbidities and
complications, including type 2 diabetes and metabolic dysfunction‐associated steatotic …

Simple Summary Obesity and metabolic syndrome are major drivers of metabolic liver
disease and liver cancer. While caloric restriction can abrogate many of the deleterious …

Background: The concept of time-restricted eating (TRE) or time-restricted feeding (TRF)
promotes daily periods of feeding and fasting to determine whole-body physiology. Chronic …

This review provides a practical and comprehensive overview of non-pharmacological
interventions for metabolic-associated fatty liver disease (MASLD), focusing on dietary and …

Context Intermittent fasting (IF) is a diet strategy with alternate intervals of calorie reduction
and normal eating. Despite its beneficial effects on weight loss and cardiometabolic risk …